CN116063492A - 嵌合和人源化抗人类ctla4单克隆抗体和其用途 - Google Patents

嵌合和人源化抗人类ctla4单克隆抗体和其用途 Download PDF

Info

Publication number
CN116063492A
CN116063492A CN202210802423.XA CN202210802423A CN116063492A CN 116063492 A CN116063492 A CN 116063492A CN 202210802423 A CN202210802423 A CN 202210802423A CN 116063492 A CN116063492 A CN 116063492A
Authority
CN
China
Prior art keywords
ctla4
antibody
mice
antibodies
ctla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202210802423.XA
Other languages
English (en)
Chinese (zh)
Inventor
Y.刘
P.郑
M.德文波特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Onco Pharmaceuticals
Original Assignee
Onco Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onco Pharmaceuticals filed Critical Onco Pharmaceuticals
Publication of CN116063492A publication Critical patent/CN116063492A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202210802423.XA 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途 Pending CN116063492A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201562267735P 2015-12-15 2015-12-15
US62/267,735 2015-12-15
US201662309169P 2016-03-16 2016-03-16
US62/309,169 2016-03-16
US201662359036P 2016-07-06 2016-07-06
US62/359,036 2016-07-06
PCT/US2016/066698 WO2017106372A1 (en) 2015-12-15 2016-12-14 Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
CN201680073425.2A CN108430499B (zh) 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680073425.2A Division CN108430499B (zh) 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途

Publications (1)

Publication Number Publication Date
CN116063492A true CN116063492A (zh) 2023-05-05

Family

ID=59057509

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210802423.XA Pending CN116063492A (zh) 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途
CN201680073425.2A Active CN108430499B (zh) 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680073425.2A Active CN108430499B (zh) 2015-12-15 2016-12-14 嵌合和人源化抗人类ctla4单克隆抗体和其用途

Country Status (26)

Country Link
US (3) US10618960B2 (https=)
EP (2) EP3389699B1 (https=)
JP (5) JP6858779B2 (https=)
KR (2) KR20250108763A (https=)
CN (2) CN116063492A (https=)
AU (3) AU2016370648B2 (https=)
BR (1) BR112018012113A2 (https=)
CA (1) CA3006984C (https=)
DK (1) DK3389699T5 (https=)
ES (1) ES2979210T3 (https=)
FI (1) FI3389699T3 (https=)
HR (1) HRP20240719T1 (https=)
HU (1) HUE066907T2 (https=)
IL (3) IL310404A (https=)
LT (1) LT3389699T (https=)
MX (3) MX2018006925A (https=)
MY (1) MY186974A (https=)
PL (1) PL3389699T3 (https=)
PT (1) PT3389699T (https=)
RS (1) RS65703B1 (https=)
SG (1) SG11201804969PA (https=)
SI (1) SI3389699T1 (https=)
SM (1) SMT202400211T1 (https=)
TW (1) TWI739781B (https=)
WO (1) WO2017106372A1 (https=)
ZA (1) ZA201804077B (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
ES3059995T3 (en) * 2016-09-19 2026-03-24 Oncoc4 Inc Cd80 and cd86 binding protein compositions and uses thereof
DK3551660T5 (da) 2016-12-07 2024-09-02 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
JP2021502100A (ja) * 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド 新規抗ｐｄ−１配列を用いた二重特異性および単一特異性抗体
KR102834864B1 (ko) * 2018-02-02 2025-07-16 온코씨4, 아이앤씨. 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체
WO2019148444A1 (en) * 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
WO2019152413A1 (en) * 2018-02-02 2019-08-08 Oncoimmune, Inc. Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
CN112399973B (zh) * 2018-06-05 2022-12-16 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
KR20210108978A (ko) 2018-12-21 2021-09-03 오제 이뮈노테라프틱스 이작용성 항-pd-1/il-7 분자
SG11202106764YA (en) * 2018-12-27 2021-07-29 Gigagen Inc Anti-ctla-4 binding proteins and methods of use thereof
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2021122866A1 (en) 2019-12-17 2021-06-24 Ose Immunotherapeutics Bifunctional molecules comprising an il-7 variant
JP7440724B2 (ja) * 2020-04-13 2024-02-29 ビオシオン インコーポレイテッド Ｃｔｌａ４に結合する抗体及びその使用
AU2021262609A1 (en) 2020-05-01 2022-12-22 Kashiv Biosciences, Llc An improved process of purification of protein
WO2022112198A1 (en) 2020-11-24 2022-06-02 Worldwide Innovative Network Method to select the optimal immune checkpoint therapies
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022169269A1 (ko) * 2021-02-03 2022-08-11 주식회사 유틸렉스 항 ctla-4 항체 및 이의 용도
MX2023011964A (es) 2021-04-09 2024-01-08 Ose Immunotherapeutics Nuevo andamio para moléculas bifuncionales con propiedades mejoradas.
EP4320156A1 (en) 2021-04-09 2024-02-14 Ose Immunotherapeutics Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
JP7345889B2 (ja) * 2021-06-17 2023-09-19 株式会社ニューギン 遊技機
AU2022359021A1 (en) * 2021-10-08 2024-05-02 Kashiv Biosciences, Llc Separation of pre-peak in fusion protein sample by using size exclusion high performance liquid chromatography
EP4392156A4 (en) * 2021-10-08 2025-06-25 Kashiv Biosciences, LLC Separation of pre-peak and post-peak in fusion protein sample by using size exclusion high performance liquid chromatography
JP2024540152A (ja) * 2021-10-29 2024-10-31 オンコシーフォー、インク． 抗ｃｔｌａ－４抗体投与レジメン
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
WO2024003360A1 (en) 2022-07-01 2024-01-04 Institut Curie Biomarkers and uses thereof for the treatment of neuroblastoma
JP2025525886A (ja) 2022-08-02 2025-08-07 オーエスイー・イミュノセラピューティクス Ｃｄ２８に対する多機能性分子
JP2025531229A (ja) 2022-09-16 2025-09-19 オンコシーフォー、インク． 腺様嚢胞がんを処置するための抗ｃｔｌａ－４抗体の使用
EP4680728A1 (en) 2023-03-17 2026-01-21 Quell Therapeutics Limited Treg therapy
EP4687991A1 (en) 2023-03-30 2026-02-11 Ose Immunotherapeutics Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof
WO2024200820A1 (en) 2023-03-30 2024-10-03 Ose Immunotherapeutics Method of synthesis of targeted lipid nanoparticle and uses thereof
KR20260005250A (ko) 2023-04-28 2026-01-09 온코씨4, 아이앤씨. 항-ctla-4 항체와 항-pd-1 항체의 조합 및 이의 치료적 용도
EP4724498A2 (en) * 2023-06-09 2026-04-15 The Regents of the University of California Methods for identifying and correcting tumor humoral immune dysfunction
WO2025133186A1 (en) 2023-12-22 2025-06-26 OncoC4, Inc. Anti-ctla-4 antibody for treatment of patients with prostate cancer and combination therapy with a radioligand therapeutic agent
WO2025201659A1 (en) 2024-03-28 2025-10-02 BioNTech SE Combination therapy comprising therapeutic rna cancer vaccines and anti-ctla4 antibodies for cancer treatment
WO2025234450A1 (ja) * 2024-05-08 2025-11-13 学校法人帝京平成大学 改変がん細胞及びそれを含むがんワクチン組成物
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2026041780A2 (en) 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment
WO2026057739A1 (en) 2024-09-12 2026-03-19 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and anti-pd-1 antibodies for platinum-resistant ovarian cancer treatment
WO2026068705A1 (en) 2024-09-26 2026-04-02 Ose Immunotherapeutics Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086014A1 (en) * 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
CN101628940A (zh) * 2008-07-15 2010-01-20 中国科学院生物物理研究所 一种单克隆抗体及其应用
CN104114701A (zh) * 2011-12-22 2014-10-22 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用
US20150322119A1 (en) * 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
JP5004390B2 (ja) 1999-08-23 2012-08-22 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 新規ｂ７−４分子およびその用途
US6803192B1 (en) 1999-11-30 2004-10-12 Mayo Foundation For Medical Education And Research B7-H1, a novel immunoregulatory molecule
DK1234031T3 (en) 1999-11-30 2017-07-03 Mayo Foundation B7-H1, AN UNKNOWN IMMUNE REGULATORY MOLECULE
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2466279A1 (en) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20090252741A1 (en) * 2004-09-08 2009-10-08 Ohio State University Research Foundation Human monoclonal anti-ctla4 antibodies in cancer treatment
US20080152655A1 (en) * 2004-09-08 2008-06-26 The Ohio State University Research Foundation Combination Therapy With Anti-Ctla4 and Anti-4-1BB Antibodies
CA2583741C (en) 2004-10-15 2014-10-14 Verisign, Inc. An algorithm to create and validate a one time password
CN101146826A (zh) * 2005-01-24 2008-03-19 得克萨斯大学体系董事会 与磷脂酰丝氨酸结合的fc融合构建体及其治疗用途
DK2439273T3 (da) * 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
US8062852B2 (en) 2007-10-01 2011-11-22 The Children's Hospital And Regional Medical Center Detection and treatment of autoimmune disorders
GB0903325D0 (en) * 2009-02-26 2009-04-08 Univ Aberdeen Antibody molecules
GB201103955D0 (en) * 2011-03-09 2011-04-20 Antitope Ltd Antibodies
WO2013142796A2 (en) * 2012-03-23 2013-09-26 Bristol-Myers Squibb Company Methods of treatments using ctla4 antibodies
US20160145355A1 (en) * 2013-06-24 2016-05-26 Biomed Valley Discoveries, Inc. Bispecific antibodies
ES3059995T3 (en) 2016-09-19 2026-03-24 Oncoc4 Inc Cd80 and cd86 binding protein compositions and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020086014A1 (en) * 1999-08-24 2002-07-04 Korman Alan J. Human CTLA-4 antibodies and their uses
CN101628940A (zh) * 2008-07-15 2010-01-20 中国科学院生物物理研究所 一种单克隆抗体及其应用
CN104114701A (zh) * 2011-12-22 2014-10-22 弗·哈夫曼-拉罗切有限公司 表达载体组织、新的生产用细胞产生方法及其在重组产生多肽中的用途
US20150322119A1 (en) * 2012-12-03 2015-11-12 Bristol-Myers Squibb Company Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
CN104292334A (zh) * 2014-04-25 2015-01-21 河南省健康伟业生物医药研究股份有限公司 一种全人源抗ctla-4单克隆抗体、制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MAY KF JR 等: "Anti-human CTLA-4 monoclonal antibody promotes T-cell expansion and immunity in a hu-PBL-SCID model: a new method for preclinical screening of costimulatory monoclonal antibodies", IMMUNOBIOLOGY, vol. 105, no. 3, 1 February 2005 (2005-02-01), pages 1114 - 1120 *
XUEXIANG DU等: "Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice", CELL RESEARCH, vol. 28, no. 4, 30 April 2018 (2018-04-30), pages 433 - 447 *

Also Published As

Publication number Publication date
MX2025001300A (es) 2025-03-07
PL3389699T3 (pl) 2024-07-22
MY186974A (en) 2021-08-26
EP4374926A2 (en) 2024-05-29
US20190127468A1 (en) 2019-05-02
JP7286845B2 (ja) 2023-06-05
CN108430499B (zh) 2022-07-19
IL259988B2 (en) 2023-02-01
KR20250108763A (ko) 2025-07-15
NZ743013A (en) 2025-03-28
IL296354B2 (en) 2024-07-01
AU2023203169A1 (en) 2023-06-15
JP2023106547A (ja) 2023-08-01
IL296354A (en) 2022-11-01
US20200283526A1 (en) 2020-09-10
SG11201804969PA (en) 2018-07-30
CA3006984A1 (en) 2017-06-22
AU2026200849A1 (en) 2026-02-26
JP7790837B2 (ja) 2025-12-23
HUE066907T2 (hu) 2024-09-28
HRP20240719T1 (hr) 2024-09-13
RS65703B1 (sr) 2024-07-31
US10618960B2 (en) 2020-04-14
EP3389699A4 (en) 2019-07-10
IL296354B1 (en) 2024-03-01
AU2023203169B2 (en) 2025-11-27
IL259988A (en) 2018-07-31
SMT202400211T1 (it) 2024-07-09
KR102830926B1 (ko) 2025-07-08
JP2021100957A (ja) 2021-07-08
DK3389699T5 (da) 2024-09-23
TWI739781B (zh) 2021-09-21
BR112018012113A2 (pt) 2018-12-04
US20230391870A1 (en) 2023-12-07
ES2979210T3 (es) 2024-09-24
MX2025001302A (es) 2025-03-07
FI3389699T3 (fi) 2024-05-28
LT3389699T (lt) 2024-06-10
US12473362B2 (en) 2025-11-18
TW201731877A (zh) 2017-09-16
AU2016370648B2 (en) 2023-03-09
JP6858779B2 (ja) 2021-04-14
WO2017106372A1 (en) 2017-06-22
AU2016370648A1 (en) 2018-06-21
MX2018006925A (es) 2018-08-01
JP2019510733A (ja) 2019-04-18
EP4374926A3 (en) 2024-08-07
IL259988B (en) 2022-10-01
EP3389699A1 (en) 2018-10-24
SI3389699T1 (sl) 2024-07-31
JP2022123049A (ja) 2022-08-23
ZA201804077B (en) 2019-09-25
US11629188B2 (en) 2023-04-18
EP3389699B1 (en) 2024-05-01
IL310404A (en) 2024-03-01
JP2025160458A (ja) 2025-10-22
DK3389699T3 (da) 2024-05-13
CN108430499A (zh) 2018-08-21
KR20180086219A (ko) 2018-07-30
PT3389699T (pt) 2024-06-04
CA3006984C (en) 2023-10-17

Similar Documents

Publication Publication Date Title
JP7790837B2 (ja) キメラ及びヒト化抗ヒトｃｔｌａ４モノクローナル抗体ならびにその使用
CN106414489A (zh) 抗-b7-h5抗体及其用途
TWI884911B (zh) 具有改良之免疫療效但減弱之副作用之突變抗ctla-4抗體
KR20200142498A (ko) 암 치료를 위한 더 안전하고 더 효과적인 항-ctla-4 항체를 선택하고 설계하는 방법
TW202305005A (zh) 抗ｓｉｇｌｅｃ組合物及其用途
HK40092659A (zh) 嵌合和人源化抗人类ctla4单克隆抗体和其用途
HK40110941A (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
HK1259883B (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
HK1259883A1 (en) Chimeric and humanized anti-human ctla4 monoclonal antibodies and uses thereof
EA038617B1 (ru) Химерные и гуманизированные античеловеческие ctla-4 моноклональные антитела и их использование
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092659

Country of ref document: HK